Supplement: Novel Cancer Immunotherapy Combos
Researchers Contextualize Immuno-Oncology Mechanisms to Advance Personalized Therapies
“Father of Gene Therapy” to be Released from Prison Next Month
W. French Anderson Intends to Resume a Career in Science
True CRISPR: A Genetic Genre with Novel Twists
With Multiplexing, Nanodelivery, and Other Advances, CRISPR Reality Outstrips CRISPR Fiction
New Group Promotes AI, Robotics, and Automation in Healthcare
Goal Is to Improve Patient Access to Quality Care
Marc Semigran M.D.
Marc Semigran, M.D., is the chief medical officer for MyoKardia. Previously, he led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School, where he also earned his A.B., A.M. and M.D. degrees.
More GEN Content From This Contributor
- GEN Exclusives: Why Cardiology Is Ripe to Become the Next Frontier for Precision Medicine
- Feature Articles: Why Cardiology Is the Next Frontier for Precision Medicine